GliaCure will carry out a Phase 1b multiple ascending dose (MAD) study in mild-to-moderate Alzheimer's disease patients to test its compound, GC021109. The study will include 36 patients, divided into 3 cohorts of 12 patients each. Each cohort will receive an increasing dose of GC021109 for 28 days. The major aim of this study is to determine the safety and tolerability of GC021109; however, various samples will be drawn from patients to determine if there are changes in biomarkers related to Alzheimer's disease and to gain information necessary to plan for a Phase 2 trial in which GC021109 efficacy in patients will begin to be evaluated.